@article{pmid40293492,

title = {RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings},

author = {Cay-Benedict von der Decken and Stefan Kleinert and Matthias Englbrecht and Kirsten Karberg and Georg Gauler and Monika Ronneberger and Praxedis Rapp and Florian Schuch and Joerg Wendler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Peter Bartz-Bazzanella},

doi = {10.1007/s00296-025-05861-z},

issn = {1437-160X},

year  = {2025},

date = {2025-04-01},

journal = {Rheumatol Int},

volume = {45},

number = {5},

pages = {129},

abstract = {More efficient means of identifying patients with inflammatory rheumatic diseases (IRDs) could allow earlier diagnosis and treatment. The objective of this study was to evaluate the characteristics of a revised version of an online patient questionnaire-based self-referral tool, RhePort 1.3. This prospective study included adult patients with musculoskeletal complaints presenting for a first rheumatology visit at German RheumaDatenRhePort (RHADAR) rheumatology network centers. All patients completed the RhePort 1.3 questionnaire on patient characteristics and symptoms. Data from RhePort 1.3 were compared with historical data from previous versions. Of 614 patients, 225 (36.6%) were diagnosed with an IRD by a rheumatologist and 164/225 IRD patients (72.9%) had a RhePort 1.3 score > 1, the cut-off point used to determine the need for rheumatologic evaluation. A score > 1 was associated with an approximately two-fold higher IRD risk (odds ratio [95% confidence interval] of 1.98 [1.39, 2.83] vs ≤ 1) and had good sensitivity (73%) and moderate specificity (42%). Among patients referred through a standard referral pathway (n = 283), RhePort 1.3 scores > 1 in addition to physician referral were associated with increases in rheumatology-diagnosed IRD rates from 33.2% (physician referral only) to 45.7%. RhePort 1.3 had higher accuracy than earlier versions (54% vs 35%). We conclude that modest changes to the RhePort questionnaire resulted in increased accuracy. A score > 1 was associated with a doubled risk for an IRD and higher IRD rates in physician-referred patients. These data suggest that RhePort has the potential to streamline the rheumatologist's workload and improve resource use. Further modifications are required to improve specificity.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid40232336,

title = {Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database},

author = {Linus Maximilian Risser and Torsten Witte and Matthias Englbrecht and Patrick-Pascal Strunz and Matthias Froehlich and Marc Schmalzing and Michael Gernert and Peter Bartz-Bazzanella and Cay von der Decken and Kirsten Karberg and Georg Gauler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Stefan Kleinert},

doi = {10.1007/s00296-025-05859-7},

issn = {1437-160X},

year  = {2025},

date = {2025-04-01},

journal = {Rheumatol Int},

volume = {45},

number = {5},

pages = {100},

abstract = {Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept, interleukin-6 inhibitors (IL-6i) and tumor necrosis factor inhibitors (TNFi). Real-world data regarding treatment persistence and drug survival in the time period following the approval of JAKI are limited. To investigate the persistence and drug survival of different (b/tsDMARDs) in patients with RA based on real-world data from German outpatients. We performed a retrospective analysis of RA patients in the German RHADAR database who received a newly prescribed therapy with a b/tsDMARD between January 15, 2015 and October 17, 2023. To compare drug survival, we used Cox regression analyses adjusted for age, sex and disease duration. We included 4678 patients (79.9% female, mean age 58.7 years, mean disease duration 11.7 years). TNFi (47.8%) and JAKi (29.4%) were most frequently prescribed. The five-year drug survival rate was highest for JAKi (68.3%), followed by TNFi (58.6%), IL-6i (58.6%), abatacept (55.0%), and rituximab (53.3%). Compared to JAKi, Cox regression showed a higher discontinuation risk for rituximab (HR 1.36, p = 0.015), abatacept (HR 1.46, p < 0.001), IL-6i (HR 1.20, p = 0.026), and TNFi (HR 1.29, p < 0.001). Rituximab had the highest two-year survival (70.3%) but a sharp decline afterward, with 60% of discontinuations occurring between March 2020 and July 2022. In a real-world setting in German outpatients with RA, JAKi was associated with longer drug survival than bDMARDS. There were no significant differences in treatment persistence among different bDMARDs.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid39836353,

title = {Real-World-Evidence of Digital Health Applications (DiGAs) in Rheumatology: Insights from the DiGAReal Registry},

author = {Alexander Albrecht and Jule Taubmann and Ioanna Minopoulou and Lukas Hatscher and Stefan Kleinert and Felix Mühlensiepen and Martin Welcker and Jan Leipe and Nils Schulz and Philipp Klemm and Axel Hueber and Georg Schett and Sebastian Kuhn and Hannah Labinsky and Johannes Knitza},

doi = {10.1007/s40744-025-00744-y},

issn = {2198-6576},

year  = {2025},

date = {2025-04-01},

journal = {Rheumatol Ther},

volume = {12},

number = {2},

pages = {267--282},

abstract = {INTRODUCTION: Prescribable digital health applications (DiGAs) present scalable solutions to improve patient self-management in rheumatology, however real-world evidence is scarce. Therefore, we aimed to assess the effectiveness, usage, and usability of DiGAs prescribed by rheumatologists, as well as patient satisfaction.



METHODS: The DiGAReal registry includes adult patients with rheumatic conditions who received a DiGA prescription. Data at baseline (T0) and the 3-month follow-up (T1) were collected through electronic questionnaires. Study outcomes included DiGA-specific outcome assessments as well as generic outcome assessments, including the Patient Global Impression of Change (PGIC), Patient Activation Measure (PAM®), and the German Telehealth Usability and Utility Short Questionnaire (TUUSQ). Changes between T0 and T1 were analyzed using descriptive statistics and paired tests.



RESULTS: A total of 191 patients were included between June 2022 and April 2023. Of these, 127 completed the 3-month follow-up, and 114 reported using the prescribed DiGA, with 66% reporting weekly use and 15% completing the full DiGA program. The most commonly prescribed DiGAs targeted pain management (53%). Symptom improvement was reported by 51% of patients using a DiGA, with significant reductions in exhaustion levels (p = 0.03). Significant DiGA-specific improvements were observed for DiGAs addressing back pain (p = 0.05) and insomnia (p = 0.006). However, no overall significant changes were detected in patient activation, health literacy, pain, overall health, or disease activity. Back pain and weight management DiGAs were the most effective, frequently used, and best-rated DiGAs, with symptom improvements reported by 50% to 82% of patients.



CONCLUSION: The findings suggest that DiGAs can improve symptom management in rheumatic patients, especially for conditions like back pain and weight control. Further real-world evidence is needed and may support value-based digital health efforts and reimbursement frameworks.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10367,

title = {Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study},

author = {Patrick-Pascal Strunz and Linus Maximilian Risser and Matthias Englbrecht and Torsten Witte and Matthias Froehlich and Marc Schmalzing and Michael Gernert and Sebastian Hueper and Peter Bartz-Bazzanella and Cay Decken and Kirsten Karberg and Georg Gauler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Stefan Kleinert},

doi = {10.3389/fimmu.2024.1445680},

issn = {1664-3224},

year  = {2024},

date = {2024-01-01},

journal = {Frontiers in Immunology},

volume = {15},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10337,

title = {Long-term cardio-vascular risk in patients with rheumatic diseases – Results of a 17 year Follow Up study [abstract]},

author = {Matthias Fröhlich and Marc Schmalzing and Stefan Stoerk and Michael Gernert and Hanna Purucker and Stefan Kleinert and Margret Breunig and Patrick P. Strunz and Hannah Labinsky and Peter U. Heuschmann and Viktoria Rücker and Caroline Morbach},

doi = {10.1136/annrheumdis-2024-eular.4323},

year  = {2024},

date = {2024-01-01},

journal = {Ann Rheum Dis},

volume = {83},

pages = {1153},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10322b,

title = {Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices},

author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and M. Welcker},

url = {https://www.ncbi.nlm.nih.gov/pubmed/37805981},

doi = {10.1007/s00296-023-05463-7},

issn = {1437-160X (Electronic) 

0172-8172 (Linking)},

year  = {2024},

date = {2024-01-01},

journal = {Rheumatol Int},

volume = {44},

number = {4},

pages = {653-661},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10334,

title = {Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial},

author = {J. Rech and K. Tascilar and M. Hagen and A. Kleyer and B. Manger and V. Schoenau and A. J. Hueber and S. Kleinert and X. Baraliakos and J. Braun and U. Kiltz and M. Fleck and A. Rubbert-Roth and D. M. Kofler and F. Behrens and M. Feuchtenberger and M. Zaenker and R. Voll and N. Venhoff and J. Thiel and C. Glaser and E. Feist and G. R. Burmester and K. Karberg and J. Strunk and J. D. Canete and L. Senolt and M. Filkova and E. Naredo and R. Largo and G. Kronke and M. A. D'Agostino and M. Ostergaard and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/38364841},

doi = {10.1016/S0140-6736(23)02650-8},

issn = {1474-547X (Electronic) 

0140-6736 (Linking)},

year  = {2024},

date = {2024-01-01},

journal = {Lancet},

volume = {403},

number = {10429},

pages = {850-859},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10366,

title = {Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network},

author = {P. P. Strunz and M. Englbrecht and L. M. Risser and T. Witte and M. Froehlich and M. Schmalzing and M. Gernert and A. Schmieder and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and J. Heck and M. Welcker and S. Kleinert},

url = {https://www.ncbi.nlm.nih.gov/pubmed/39136784},

doi = {10.1007/s00296-024-05671-9},

issn = {1437-160X (Electronic) 

0172-8172 (Linking)},

year  = {2024},

date = {2024-01-01},

journal = {Rheumatol Int},

abstract = {In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe forms of axial spondyloarthritis (axSpA). Drug survival in axSpA patients has not been well studied in a real-world outpatient scenario since the approval of JAKi. We aimed to analyze the three drug classes based on modes of actions (MoA) for their persistence rates among German axSpA outpatients. A retrospective analysis of the RHADAR database for axSpA patients with a new initiation of TNFi, IL-17i, or JAKi treatment between January 2015 and October 2023 was conducted. Analyses included Kaplan-Meier curves and adjusted Cox regressions for drug discontinuation. 1222 new biological DMARD (TNFi [n = 954], IL-17i [n = 190]) or JAKi (n = 78) treatments were reported. The median drug survival was 31 months for TNFi, 25 for IL-17i, and 18 for JAKi. The corresponding 2-year drug survival rate was 79.6%, 72.6%, and 62.8% for TNFi, IL-17i, and JAKi, respectively. The probability for discontinuation for JAKi was significantly higher compared with TNFi (HR 1.91 [95% CI 1.22-2.99]) as well as for IL-17i compared with TNFi (HR 1.43 [95% CI 1.02-2.01]), possibly related to more frequent use of TNFis as first-line therapy. IL-17i and JAKi discontinuation probabilities were similar. Primary non-response was the reason for drug discontinuation in most cases across all MoA. TNFi treatment might persist longer than JAKi and IL-17i in German axSpA outpatients, possibly related to more severe or refractory disease in patients with JAKi-treated or IL-17i-treated axSpA.},

note = {Strunz, Patrick-Pascal 

Englbrecht, Matthias 

Risser, Linus Maximilian 

Witte, Torsten 

Froehlich, Matthias 

Schmalzing, Marc 

Gernert, Michael 

Schmieder, Astrid 

Bartz-Bazzanella, Peter 

von der Decken, Cay 

Karberg, Kirsten 

Gauler, Georg 

Wurth, Patrick 

Spathling-Mestekemper, Susanna 

Kuhn, Christoph 

Vorbruggen, Wolfgang 

Heck, Johannes 

Welcker, Martin 

Kleinert, Stefan 

eng 

Germany 

2024/08/13 

Rheumatol Int. 2024 Aug 13. doi: 10.1007/s00296-024-05671-9.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10351,

title = {Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database},

author = {P. P. Strunz and M. Englbrecht and L. M. Risser and T. Witte and M. Froehlich and M. Schmalzing and M. Gernert and A. Schmieder and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and J. Heck and M. Welcker and S. Kleinert},

url = {https://www.ncbi.nlm.nih.gov/pubmed/38846940},

doi = {10.3389/fimmu.2024.1395968},

issn = {1664-3224 (Electronic) 

1664-3224 (Linking)},

year  = {2024},

date = {2024-01-01},

journal = {Front Immunol},

volume = {15},

pages = {1395968},

abstract = {OBJECTIVE: Treatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs; interleukin [IL]-23 inhibitors [IL-23i], IL-12/23 inhibitors [IL-12/23i], tumor necrosis factor inhibitors [TNFi], and IL-17 inhibitors [IL-17i]) are currently approved for moderate to severe PsA treatment. There is minimal evidence of the persistence of these drugs among PsA outpatients in a real-world scenario during the period following the approval of JAKi. Therefore, we aimed to analyze the drug survival rates of biologic and JAKi therapies among German PsA outpatients during routine clinical care. METHODS: We retrospectively analyzed PsA patients with a new prescription for a biologic or JAKi in the RHADAR database between January 2015 and October 2023. Kaplan-Meier Curves and Cox regression modelling were used to compare drug survival rates. RESULTS: 1352 new prescriptions with bDMARDs (IL-12/23i [n=50], IL-23i [n=31], TNFi [n=774], IL-17i [n=360]) or JAKi (n=137) were identified. The 5-year drug survival rate was 67.8% for IL-17i, 62.3% for TNFi, 53.3% for JAKi, and 46.0% for IL-12/23i. Discontinuation probabilities for JAKi and IL-12/23i were significantly higher compared with TNFi (JAKi hazard ratio [HR] 1.66, [95% CI 1.23-2.24]},

note = {Strunz, Patrick-Pascal 

Englbrecht, Matthias 

Risser, Linus Maximilian 

Witte, Torsten 

Froehlich, Matthias 

Schmalzing, Marc 

Gernert, Michael 

Schmieder, Astrid 

Bartz-Bazzanella, Peter 

von der Decken, Cay 

Karberg, Kirsten 

Gauler, Georg 

Wurth, Patrick 

Spathling-Mestekemper, Susanna 

Kuhn, Christoph 

Vorbruggen, Wolfgang 

Heck, Johannes 

Welcker, Martin 

Kleinert, Stefan 

eng 

Switzerland 

2024/06/07 

Front Immunol. 2024 May 23;15:1395968. doi: 10.3389/fimmu.2024.1395968. eCollection 2024.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37297917,

title = {Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial},

author = {Marlene Stephan and Koray Tascilar and Melek Yalcin-Mutlu and Melanie Hagen and Judith Haschka and Michaela Reiser and Fabian Hartmann and Arnd Kleyer and Axel J Hueber and Bernhard Manger and Camille Figueiredo and Jayme Fogagnolo Cobra and Hans-Peter Tony and Stephanie Finzel and Stefan Kleinert and Jörg Wendler and Florian Schuch and Monika Ronneberger and Martin Feuchtenberger and Martin Fleck and Karin Manger and Wolfgang Ochs and Matthias Schmitt-Haendle and Hannes Martin Lorenz and Hubert Nüsslein and Rieke Alten and Joerg Henes and Klaus Krüger and Georg Schett and Jürgen Rech},

doi = {10.3390/jcm12113723},

issn = {2077-0383},

year  = {2023},

date = {2023-05-01},

journal = {J Clin Med},

volume = {12},

number = {11},

abstract = {Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10244,

title = {Röntgenologische versus non-röntgenologische axiale Spondyloarthritis - Auch ein Real-World-Klassifikation},

author = {Stefan Kleinert and Praxedis Rapp and Florian Schuch and Monika Ronneberger and Joerg Wendler and Patrizia Sternad and Florian Popp and Peter Bartz-Bazzanella and Cay von der Decken and Kirsten Karberg and Georg Gauler and Patrick Wurth and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker},

doi = {https://dx.doi.org/10.3205/23dgrh184},

year  = {2023},

date = {2023-01-01},

journal = {Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10336,

title = {Eine Applikation für die rheumatologische Versorgung: RheCORD},

author = {Martin Welcker and Michael Klennert and Peer Aries and Peter Bartz-Bazzanella and Cay Von der Decken and Matthias Engelbrecht and Georg Gauler and Johannes Hornig and Kirsten Karberg and Christoph Kuhn and Florian Schuch and Susanna Späthling-Mestekemper and Wolfgang Vorbrüggen and Patrick Wurth and Theresia Muth and Sonja Froschauer-Häfele and Felix Mühlensiepen and Florian Popp and Kristin Burigk and Heike Kladny and Stefan Kleinert},

url = {http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2113-5577},

doi = {10.1055/a-2113-5577},

issn = {0341-051X 

1438-9940},

year  = {2023},

date = {2023-01-01},

journal = {Aktuelle Rheumatologie},

volume = {48},

number = {04},

pages = {263-269},

abstract = {Heutzutage haben medizinische Gesundheits-Applikationen (Apps) einen zunehmenden Stellenwert. Auf nahezu jedem neuen Smartphone sind Gesundheits-Applikationen installiert. RheCORD, eine medizinische Applikation in der Rheumatologie, wird im Folgenden beschrieben und im medizinischen Kontext bewertet. Einsatzmöglichkeiten,Vorteile und Limitationen werden beschrieben.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10032,

title = {Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis},

author = { S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. von der Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbruggen and G. Adler and M. Welcker},

url = {https://www.ncbi.nlm.nih.gov/pubmed/36441274},

doi = {10.1007/s00296-022-05248-4},

issn = {1437-160X (Electronic) 

0172-8172 (Linking)},

year  = {2023},

date = {2023-01-01},

journal = {Rheumatol Int},

volume = {43},

number = {1},

pages = {89-97},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10038,

title = {Analyzing web searches for axial spondyloarthritis in Germany: a novel approach to exploring interests and unmet needs},

author = { K. Berr and L. Tizek and M. C. Schielein and M. Welcker and J. Knitza and S. Kleinert and A. Zink},

url = {https://www.ncbi.nlm.nih.gov/pubmed/36640175 

https://link.springer.com/content/pdf/10.1007/s00296-023-05273-x.pdf},

doi = {10.1007/s00296-023-05273-x},

issn = {1437-160X (Electronic) 

0172-8172 (Linking)},

year  = {2023},

date = {2023-01-01},

journal = {Rheumatol Int},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10245,

title = {RhePORT – Effizienz hinsichtlich personeller Ressourcen und Patientenselektion – Bewährung im Praxisalltag!},

author = {S. Kleinert and K. Burigk and S. Baltrusch and M. Ronneberger and P. Rapp and J. Wendler and F. Schuch and M. Welcker and C. von der Decken and P. Bartz-Bazzanella and W. Vorbrüggen},

doi = {https://dx.doi.org/10.3205/23dgrh236},

year  = {2023},

date = {2023-01-01},

journal = {Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10321,

title = {Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial},

author = {M. Stephan and K. Tascilar and M. Yalcin-Mutlu and M. Hagen and J. Haschka and M. Reiser and F. Hartmann and A. Kleyer and A. J. Hueber and B. Manger and C. Figueiredo and J. F. Cobra and H. P. Tony and S. Finzel and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nüsslein and R. Alten and J. Henes and K. Krüger and G. Schett and J. Rech},

doi = {10.3390/jcm12113723},

issn = {2077-0383 (Print) 

2077-0383},

year  = {2023},

date = {2023-01-01},

journal = {J Clin Med},

volume = {12},

number = {11},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN10322,

title = {Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices},

author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and M. Welcker},

url = {https://www.ncbi.nlm.nih.gov/pubmed/37805981},

doi = {10.1007/s00296-023-05463-7},

issn = {1437-160X (Electronic) 0172-8172 (Linking)},

year  = {2023},

date = {2023-01-01},

urldate = {2023-01-01},

journal = {Rheumatol Int},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36087130,

title = {Comparison of physician and artificial intelligence-based symptom checker diagnostic accuracy},

author = {Markus Gräf and Johannes Knitza and Jan Leipe and Martin Krusche and Martin Welcker and Sebastian Kuhn and Johanna Mucke and Axel J Hueber and Johannes Hornig and Philipp Klemm and Stefan Kleinert and Peer Aries and Nicolas Vuillerme and David Simon and Arnd Kleyer and Georg Schett and Johanna Callhoff},

doi = {10.1007/s00296-022-05202-4},

issn = {1437-160X},

year  = {2022},

date = {2022-12-01},

journal = {Rheumatol Int},

volume = {42},

number = {12},

pages = {2167--2176},

abstract = {Symptom checkers are increasingly used to assess new symptoms and navigate the health care system. The aim of this study was to compare the accuracy of an artificial intelligence (AI)-based symptom checker (Ada) and physicians regarding the presence/absence of an inflammatory rheumatic disease (IRD). In this survey study, German-speaking physicians with prior rheumatology working experience were asked to determine IRD presence/absence and suggest diagnoses for 20 different real-world patient vignettes, which included only basic health and symptom-related medical history. IRD detection rate and suggested diagnoses of participants and Ada were compared to the gold standard, the final rheumatologists' diagnosis, reported on the discharge summary report. A total of 132 vignettes were completed by 33 physicians (mean rheumatology working experience 8.8 (SD 7.1) years). Ada's diagnostic accuracy (IRD) was significantly higher compared to physicians (70 vs 54%, p = 0.002) according to top diagnosis. Ada listed the correct diagnosis more often compared to physicians (54 vs 32%, p < 0.001) as top diagnosis as well as among the top 3 diagnoses (59 vs 42%, p < 0.001). Work experience was not related to suggesting the correct diagnosis or IRD status. Confined to basic health and symptom-related medical history, the diagnostic accuracy of physicians was lower compared to an AI-based symptom checker. These results highlight the potential of using symptom checkers early during the patient journey and importance of access to complete and sufficient patient information to establish a correct diagnosis.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Simon2022-wz,

title = {Impact of cytokine inhibitor therapy on the prevalence,  seroconversion rate, and longevity of the humoral immune  response against SARS-CoV-2 in an unvaccinated cohort},

author = { David Simon and Koray Tascilar and Arnd Kleyer and Filippo Fagni and Gerhard Krönke and Christine Meder and Peter Dietrich and Till Orlemann and Thorsten Kliem and Johanna Mößner and Anna-Maria Liphardt and Verena Schönau and Daniela Bohr and Louis Schuster and Fabian Hartmann and Moritz Leppkes and Andreas Ramming and Milena Pachowsky and Florian Schuch and Monika Ronneberger and Stefan Kleinert and Axel J Hueber and Karin Manger and Bernhard Manger and Raja Atreya and Carola Berking and Michael Sticherling and Markus F Neurath and Georg Schett},

url = {https://pubmed.ncbi.nlm.nih.gov/34951137/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011429/},

year  = {2022},

date = {2022-05-01},

urldate = {2022-05-01},

journal = {Arthritis Rheumatol.},

volume = {74},

number = {5},

pages = {783--790},

publisher = {Wiley},

abstract = {ÖBJECTIVE: To investigate the impact of biologic 

 disease-modifying antirheumatic drug (bDMARD) treatment on the 

 prevalence, seroconversion rate, and longevity of the humoral 

 immune response against SARS-CoV-2 in patients with 

 immune-mediated inflammatory diseases (IMIDs). METHODS: 

 Anti-SARS-CoV-2 IgG antibodies were measured in a prospective 

 cohort of health care professional controls and non-health care 

 controls and IMID patients receiving no treatment or receiving 

 treatment with conventional or biologic DMARDs during the first 

 and second COVID-19 waves. Regression models adjusting for age, 

 sex, sampling time, and exposure risk behavior were used to 

 calculate relative risks (RRs) of seropositivity. Seroconversion 

 rates were assessed in participants with polymerase chain 

 reaction (PCR)-positive SARS-CoV-2 infection. Antibody response 

 longevity was evaluated by reassessing participants who tested 

 positive during the first wave. RESULTS: In this study, 4,508 

 participants (2,869 IMID patients and 1,639 controls) were 

 analyzed. The unadjusted RR (0.44 [95% confidence interval 

 (95% CI) 0.31-0.62]) and adjusted RR (0.50 [95% CI 0.34-0.73]) 

 for SARS-CoV-2 IgG antibodies were significantly lower in IMID 

 patients treated with bDMARDs compared to non-health care 

 controls (P < 0.001), primarily driven by treatment with tumor 

 necrosis factor inhibitors, interleukin-17 (IL-17) inhibitors, 

 and IL-23 inhibitors. Adjusted RRs for untreated IMID patients 

 (1.12 [95% CI 0.75-1.67]) and IMID patients receiving 

 conventional synthetic DMARDs (0.70 [95% CI 0.45-1.08]) were 

 not significantly different from non-health care controls. Lack 

 of seroconversion in PCR-positive participants was more common 

 among bDMARD-treated patients (38.7%) than in non-health care 

 controls (16%). Overall, 44% of positive participants lost 

 SARS-CoV-2 antibodies by follow-up, with higher rates in IMID 

 patients treated with bDMARDs (RR 2.86 [95% CI 1.43-5.74]). 

 CONCLUSION: IMID patients treated with bDMARDs have a lower 

 prevalence of SARS-CoV-2 antibodies, seroconvert less frequently 

 after SARS-CoV-2 infection, and may exhibit a reduced longevity 

 of their humoral immune response."},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9958,

title = {Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?},

author = { M. Englbrecht and P. Bartz-Bazzanella and C. von der Decken and G. Gauler and P. Wurth and P. Aries and K. Karberg and C. Kuhn and F. Schuch and S. Spathling-Mestekemper and W. Vorbruggen and J. Wendler and M. Welcker and S. Kleinert},

url = {https://www.ncbi.nlm.nih.gov/pubmed/34790678 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591045/pdf/fmed-08-748262.pdf},

doi = {10.3389/fmed.2021.748262},

issn = {2296-858X (Print) 

2296-858X (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {Front Med (Lausanne)},

volume = {8},

pages = {748262},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9959,

title = {[Data analysis in rheumatology practices : Possibilities, limitations, and results]},

author = { S. Kleinert},

url = {https://www.ncbi.nlm.nih.gov/pubmed/34618210 

https://link.springer.com/content/pdf/10.1007/s00393-021-01103-2.pdf},

doi = {10.1007/s00393-021-01103-2},

issn = {1435-1250 (Electronic) 

0340-1855 (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {Z Rheumatol},

volume = {80},

number = {9},

pages = {827-834},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9809,

title = {A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry},

author = { S. Kleinert and P. Bartz-Bazzanella and C. von der Decken and J. Knitza and T. Witte and S. P. Fekete and M. Konitzny and A. Zink and G. Gauler and P. Wurth and P. Aries and K. Karberg and C. Kuhn and F. Schuch and S. Spathling-Mestekemper and W. Vorbruggen and M. Englbrecht and M. Welcker and Rhadar Group},

url = {https://www.ncbi.nlm.nih.gov/pubmed/34014170},

doi = {10.2196/28164},

issn = {1438-8871 (Electronic) 

1438-8871 (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {J Med Internet Res},

volume = {23},

number = {5},

pages = {e28164},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9667,

title = {Cognitive Impairment in axial spondyloarthritis? [abstract]},

author = { S. Kleinert and P. Rapp and F. Schuch and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. B. Von der Decken and K. Karberg and G. Gauler and P. Wurth and S. Spaethling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbrüggen and G. Adler and M. Welcker},

url = {http://ard.bmj.com/content/80/Suppl_1/1274.abstract 

https://ard.bmj.com/content/annrheumdis/80/Suppl_1/1274.full.pdf},

doi = {10.1136/annrheumdis-2021-eular.1353},

year  = {2021},

date = {2021-01-01},

journal = {Annals of the Rheumatic Diseases},

volume = {80},

number = {Suppl 1},

pages = {1274},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9671,

title = {Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial},

author = { J. Knitza and J. Mohn and C. Bergmann and E. Kampylafka and M. Hagen and D. Bohr and H. Morf and E. Araujo and M. Englbrecht and D. Simon and A. Kleyer and T. Meinderink and W. Vorbruggen and C. B. von der Decken and S. Kleinert and A. Ramming and J. H. W. Distler and N. Vuillerme and A. Fricker and P. Bartz-Bazzanella and G. Schett and A. J. Hueber and M. Welcker},

url = {https://www.ncbi.nlm.nih.gov/pubmed/33849654 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042673/pdf/13075_2021_Article_2498.pdf},

doi = {10.1186/s13075-021-02498-8},

issn = {1478-6362 (Electronic) 

1478-6354 (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {Arthritis Res Ther},

volume = {23},

number = {1},

pages = {112},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9669,

title = {SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases},

author = { D. Simon and K. Tascilar and F. Fagni and G. Kronke and A. Kleyer and C. Meder and R. Atreya and M. Leppkes and A. E. Kremer and A. Ramming and M. L. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Sticherling and M. F. Neurath and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/33958324},

doi = {10.1136/annrheumdis-2021-220461},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {Ann Rheum Dis},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9458,

title = {T cells, natural killer cells, and gammadeltaT cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy},

author = { E. C. Schwaneck and R. Renner and L. Junker and H. P. Tony and S. Kleinert and M. Gernert and M. Schmalzing and O. Gadeholt},

url = {https://www.ncbi.nlm.nih.gov/pubmed/31556339},

doi = {10.1080/03009742.2019.1634755},

issn = {1502-7732 (Electronic) 

0300-9742 (Linking)},

year  = {2020},

date = {2020-01-01},

journal = {Scand J Rheumatol},

volume = {49},

number = {1},

pages = {8-12},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9673,

title = {Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion},

author = { D. Simon and K. Tascilar and G. Kronke and A. Kleyer and M. M. Zaiss and F. Heppt and C. Meder and R. Atreya and E. Klenske and P. Dietrich and A. Abdullah and T. Kliem and G. Corte and H. Morf and M. Leppkes and A. E. Kremer and A. Ramming and M. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and C. Maier and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Tenbusch and K. Uberla and M. Sticherling and M. F. Neurath and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/32709909},

doi = {10.1038/s41467-020-17703-6},

issn = {2041-1723 (Electronic) 

2041-1723 (Linking)},

year  = {2020},

date = {2020-01-01},

journal = {Nat Commun},

volume = {11},

number = {1},

pages = {3774},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9624,

title = {Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists [abstract]},

author = { Kleinert S and Bartz-Bazzanella P and von der Decken C and Karberg K and Schuch F and Gauler G and Wurth P and Spaethling-Mestekemper S and Kuhn C and Englbrecht M and Vorbrueggen W and Welcker M.},

year  = {2020},

date = {2020-01-01},

journal = {Arthritis Rheumatol.},

volume = {72 (suppl 10).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9063,

title = {New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – Implications from the prospective multicenter VADERA II study},

author = { Matthias Englbrecht and Rieke Alten and Martin Aringer and Christoph G. Baerwald and Harald Burkhardt and Nancy Eby and Jan-Paul Flacke and Gerhard Fliedner and Ulf Henkemeier and Michael W. Hofmann and Stefan Kleinert and Christian Kneitz and Klaus Krüger and Christoph Pohl and Georg Schett and Marc Schmalzing and Anne-Kathrin Tausche and Hans-Peter Tony and Jörg Wendler},

url = {https://doi.org/10.1371/journal.pone.0217412},

doi = {10.1371/journal.pone.0217412},

year  = {2019},

date = {2019-01-01},

journal = {PLOS ONE},

volume = {14},

number = {5},

pages = {e0217412},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9615,

title = {How many of your patients have depressive symptoms? How to assess during routine clinical practice?},

author = { Stefan Kleinert and Florian Schuch and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Matthias Englbrecht},

year  = {2019},

date = {2019-01-01},

journal = {Ann Rheum Dis},

volume = {78},

pages = {A638},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9625,

title = {Dealing with comorbidities in rheumatoid arthritis with medical assistants. The patients’ opinion on assessment and education by medical assistants during routine clinical practice [abstract]},

author = { Stefan Kleinert and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Florian Schuch},

year  = {2019},

date = {2019-01-01},

journal = {Ann Rheum Dis},

volume = {78, supplement 2},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9062,

title = {Komorbiditäten und Mortalität bei Patienten mit entzündlichen Gelenkerkrankungen},

author = { Stefan Kleinert},

url = {https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0043-118005.pdf},

doi = {10.1055/s-0043-118005},

issn = {0341-051X},

year  = {2018},

date = {2018-01-01},

journal = {Akt Rheumatol},

volume = {43},

number = {02},

pages = {156-160},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9017,

title = {Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients},

author = { E. C. Schwaneck and R. Renner and L. Junker and H. Einsele and O. Gadeholt and E. Geissinger and S. Kleinert and M. Gernert and H. P. Tony and M. Schmalzing},

url = {https://www.ncbi.nlm.nih.gov/pubmed/29938921},

doi = {10.1002/art.40654},

issn = {2326-5205 (Electronic) 

2326-5191 (Linking)},

year  = {2018},

date = {2018-01-01},

journal = {Arthritis Rheumatol},

volume = {70},

number = {12},

pages = {1914-1922},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Figueiredo2017-hw,

title = {Antimodified protein antibody response pattern influences the  risk for disease relapse in patients with rheumatoid arthritis  tapering disease modifying antirheumatic drugs},

author = { Camille P Figueiredo and Holger Bang and Jayme Fogagnolo Cobra and Matthias Englbrecht and Axel J Hueber and Judith Haschka and Bernhard Manger and Arnd Kleyer and Michaela Reiser and Stephanie Finzel and Hans-Peter Tony and Stefan Kleinert and Joerg Wendler and Florian Schuch and Monika Ronneberger and Martin Feuchtenberger and Martin Fleck and Karin Manger and Wolfgang Ochs and Matthias Schmitt-Haendle and Hanns-Martin Lorenz and Hubert Nuesslein and Rieke Alten and Joerg Henes and Klaus Krueger and Jürgen Rech and Georg Schett},

year  = {2017},

date = {2017-02-01},

urldate = {2017-02-01},

journal = {Ann. Rheum. Dis.},

volume = {76},

number = {2},

pages = {399--407},

abstract = {ÖBJECTIVE: To perform a detailed analysis of the autoantibody 

 response against post-translationally modified proteins in 

 patients with rheumatoid arthritis (RA) in sustained remission 

 and to explore whether its composition influences the risk for 

 disease relapse when tapering disease modifying antirheumatic 

 drug (DMARD) therapy. METHODS: Immune responses against 10 

 citrullinated, homocitrullinated/carbamylated and acetylated 

 peptides, as well as unmodified vimentin (control) and cyclic 

 citrullinated peptide 2 (CCP2) were tested in baseline serum 

 samples from 94 patients of the RETRO study. Patients were 

 classified according to the number of autoantibody reactivities 

 (0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination, 

 carbamylation and acetylation; 0-3) and tested for their risk to 

 develop relapses after DMARD tapering. Demographic and 

 disease-specific parameters were included in multivariate 

 logistic regression analysis for defining the role of 

 autoantibodies in predicting relapse. RESULTS: Patients varied in 

 their antimodified protein antibody response with the extremes 

 from recognition of no (0/10) to all antigens (10/10). Antibodies 

 against citrullinated vimentin (51%), acetylated ornithine 

 (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011) 

 increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 

 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity) 

 to 28%, 36% and finally to 52% with one, two or three antibody 

 specificity groups, respectively. CONCLUSIONS: The data suggest 

 that the pattern of antimodified protein antibody response 

 determines the risk of disease relapse in patients with RA 

 tapering DMARD therapy. TRIAL REGISTRATION NUMBER: 

 2009-015740-42; Results."},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8199,

title = {[Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers]},

author = { K. Albrecht and D. Huscher and T. Eidner and S. Kleinert and S. Spathling-Mestekemper and S. Bischoff and A. Zink},

url = {https://www.ncbi.nlm.nih.gov/pubmed/27379740 

https://link.springer.com/article/10.1007%2Fs00393-016-0156-5},

doi = {10.1007/s00393-016-0156-5},

issn = {1435-1250 (Electronic) 

0340-1855 (Linking)},

year  = {2017},

date = {2017-01-01},

journal = {Z Rheumatol},

volume = {76},

number = {1},

pages = {50-57},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8877,

title = {Simple screening tools predict death and cardiovascular events in patients with rheumatic disease},

author = { M. Breunig and S. Kleinert and S. Lehmann and C. Kneitz and M. Feuchtenberger and H. P. Tony and C. E. Angermann and G. Ertl and S. Stork},

url = {https://www.ncbi.nlm.nih.gov/pubmed/28812405},

doi = {10.1080/03009742.2017.1337924},

issn = {1502-7732 (Electronic) 

0300-9742 (Linking)},

year  = {2017},

date = {2017-01-01},

journal = {Scand J Rheumatol},

pages = {1-8},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8198,

title = {Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge},

author = { M. Englbrecht and R. Alten and M. Aringer and C. G. Baerwald and H. Burkhardt and N. Eby and G. Fliedner and B. Gauger and U. Henkemeier and M. W. Hofmann and S. Kleinert and C. Kneitz and K. Krueger and C. Pohl and A. E. Roske and G. Schett and M. Schmalzing and A. K. Tausche and H. Peter Tony and J. Wendler},

url = {https://www.ncbi.nlm.nih.gov/pubmed/27482854 http://onlinelibrary.wiley.com/store/10.1002/acr.23002/asset/acr23002.pdf?v=1&t=j4e9fhol&s=713b86ce15fe37f619af80435413e786b0ac549f},

doi = {10.1002/acr.23002},

issn = {2151-4658 (Electronic) 

2151-464X (Linking)},

year  = {2017},

date = {2017-01-01},

journal = {Arthritis Care Res (Hoboken)},

volume = {69},

number = {1},

pages = {58-66},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8609,

title = {Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs},

author = { C. P. Figueiredo and H. Bang and J. F. Cobra and M. Englbrecht and A. J. Hueber and J. Haschka and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and J. Rech and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/27323772 

http://ard.bmj.com/content/annrheumdis/76/2/399.full.pdf},

doi = {10.1136/annrheumdis-2016-209297},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2017},

date = {2017-01-01},

journal = {Ann Rheum Dis},

volume = {76},

number = {2},

pages = {399-407},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8878,

title = {Rheumatische Krankheitserscheinungen bei hämatologischen Neoplasien},

author = { S. Kleinert and P. La Rosée and K. Krüger},

url = {https://doi.org/10.1007/s00393-017-0338-9 

https://link.springer.com/content/pdf/10.1007%2Fs00393-017-0338-9.pdf},

doi = {10.1007/s00393-017-0338-9},

issn = {1435-1250},

year  = {2017},

date = {2017-01-01},

journal = {Zeitschrift für Rheumatologie},

volume = {76},

number = {2},

pages = {38-45},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9108,

title = {Validation of standardized questionnaires evaluating symptoms of depression in rheumatoid arthritis patients - approaches to screening for a frequent and yet underrated challenge},

author = { Matthias Englbrecht and Rieke Alten and Martin Aringer and Christoph G. Baerwald and Harald Burkhardt and Nancy Eby and Gerhard Fliedner and Bettina Gauger and Ulf Henkemeier and Michael W. Hofmann and Stefan Kleinert and Christian Kneitz and Klaus Krueger and Christoph Pohl and Anne-Eve Roske and Georg Schett and Marc Schmalzing and Anne-Kathrin Tausche and Hans Peter Tony and Joerg Wendler},

url = {https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.23002},

doi = {10.1002/acr.23002},

issn = {2151-4658},

year  = {2016},

date = {2016-01-01},

journal = {Arthritis Care & Research},

pages = {n/a-n/a},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7751,

title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},

author = { J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},

url = {http://www.ncbi.nlm.nih.gov/pubmed/25660991},

doi = {10.1136/annrheumdis-2014-206439},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2016},

date = {2016-01-01},

journal = {Ann Rheum Dis},

volume = {75},

number = {1},

pages = {45-51},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8064,

title = {[Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer]},

author = { S. Kleinert and M. Waldner and J. Wendler and V. Kunzmann},

url = {http://www.ncbi.nlm.nih.gov/pubmed/26786168 http://download.springer.com/static/pdf/163/art%253A10.1007%252Fs00393-015-0032-8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00393-015-0032-8&token2=exp=1456567687~acl=%2Fstatic%2Fpdf%2F163%2Fart%25253A10.1007%25252Fs00393-015-0032-8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00393-015-0032-8*~hmac=22a15e98f1b4a995584b830b445c6680f14e09356e23796ba3df76a7f0d4004b},

doi = {10.1007/s00393-015-0032-8},

issn = {1435-1250 (Electronic) 

0340-1855 (Linking)},

year  = {2016},

date = {2016-01-01},

journal = {Z Rheumatol},

volume = {75},

number = {1},

pages = {41-6},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8206,

title = {Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment},

author = { J. Rech and A. J. Hueber and S. Finzel and M. Englbrecht and J. Haschka and B. Manger and A. Kleyer and M. Reiser and J. F. Cobra and C. Figueiredo and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/26483255 

http://ard.bmj.com/content/annrheumdis/75/9/1637.full.pdf},

doi = {10.1136/annrheumdis-2015-207900},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2016},

date = {2016-01-01},

journal = {Ann Rheum Dis},

volume = {75},

number = {9},

pages = {1637-44},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7752,

title = {The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis},

author = { M. Feuchtenberger and S. Kleinert and E. C. Scharbatke and H. Gnann and F. Behrens and B. M. Wittig and G. Greger and H. P. Tony},

url = {http://www.ncbi.nlm.nih.gov/pubmed/25897681},

issn = {0392-856X (Print) 

0392-856X (Linking)},

year  = {2015},

date = {2015-01-01},

journal = {Clin Exp Rheumatol},

volume = {33},

number = {3},

pages = {321-9},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9102,

title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},

author = { J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},

url = {https://ard.bmj.com/content/annrheumdis/75/1/45.full.pdf},

doi = {10.1136/annrheumdis-2014-206439},

issn = {0003-4967},

year  = {2015},

date = {2015-01-01},

journal = {Ann Rheum Dis},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8836,

title = {Prevalence and Relevance of Depressive Symptoms in Patients with Rheumatic Diseases [abstract]},

author = { S Kleinert and A Marx and H Faller and Feuchtenberger. M and Kneitz. C and S Lehmann and HP Tony and C Angermann and G Ertl and S Störk and M Breunig},

year  = {2015},

date = {2015-01-01},

journal = {Arthritis Rheumatol. 2015; 67 (suppl 10)},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7755,

title = {Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control},

author = { U. Müller-Ladner and S. Kleinert and K. Krüger and B. Wittig and R. Hecker},

year  = {2014},

date = {2014-01-01},

journal = {Arthritis Rheum},

volume = {66},

number = {Suppl 10},

pages = {469},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7620,

title = {Implementation of the EULAR Recommendations for Cardiovascular Risk Management in Germany: Results of a Cross-Sectional Epidemiologic Study [abstr]},

author = { K. Krüger and S. Kleinert and R. Hecker and B.M. Wittig and B. Wolff and U Müller-Ladner},

url = {https://ard.bmj.com/content/73/Suppl_2/172.3},

year  = {2014},

date = {2014-01-01},

urldate = {2014-01-01},

journal = {Ann Rheum Dis},

volume = {73},

number = {Suppl 2},

pages = {172-173},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7754,

title = {Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis},

author = { F. Behrens and H. P. Tony and R. Alten and S. Kleinert and E. C. Scharbatke and M. Kohm and H. Gnann and J. Tams and G. Greger and H. Burkhardt},

url = {http://www.ncbi.nlm.nih.gov/pubmed/23609999 http://onlinelibrary.wiley.com/store/10.1002/acr.22037/asset/acr22037.pdf?v=1&t=i8znk6tz&s=63b7d7544c8e02d0bcc49945a06435c41ffb040f},

doi = {10.1002/acr.22037},

issn = {2151-4658 (Electronic) 

2151-464X (Linking)},

year  = {2013},

date = {2013-01-01},

journal = {Arthritis Care Res (Hoboken)},

volume = {65},

number = {10},

pages = {1608-16},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7756,

title = {Evaluating Depression Questionnaires In German Rheumatoid Arthritis Patients – Preliminary Results From a Validation Study},

author = { M. Englbrecht and R. Alten and M. Aringer and CG. Baerwald and H. Burkhardt and N. Eby and G. Fliedner and B. Gauger and U. Henkemeier and M. Hofmann and S. Kleinert and C. Kneitz and C. Pohl and G. Schett and M. Schmalzing and A. Tausche and H. Tony and J. Wendler},

year  = {2013},

date = {2013-01-01},

journal = {Arthritis Rheum},

volume = {65},

number = {Suppl 10},

pages = {978},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN6068,

title = {Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death.},

author = { S. Kleinert and M. Breunig and HP Tony and M. Feuchtenberger and M. Schmalzing and C. Kneitz and S. Lehmann and C. E. Angermann and G. Ertl and S. Störk},

year  = {2013},

date = {2013-01-01},

journal = {Arthritis Rheum},

volume = {65},

number = {Suppl 10},

pages = {783},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7757,

title = {Identification of Patients at High Risk for Death in Rheumatic Diseases},

author = { S. Kleinert and M. Breunig and H.-P. Tony and M. Feuchtenberger and C. Kneitz and S. Lehmann and C. E. Angermann and G. Ertl and S. Störk},

year  = {2013},

date = {2013-01-01},

journal = {Ann Rheum Dis},

volume = {72},

number = {Suppl3},

pages = {609},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7753,

title = {A 58-year-old man with respiratory insufficiency after a 50-year history of hypersensitivity pneumonitis and pulmonary Aspergillus infections},

author = { F. Segerer and H. Morbach and N. Hassold and S. Kleinert and H. P. Tony and J. Roesler and J. Liese},

url = {http://www.ncbi.nlm.nih.gov/pubmed/24565717},

doi = {10.1016/j.jaip.2013.09.001},

issn = {2213-2201 (Electronic)},

year  = {2013},

date = {2013-01-01},

journal = {J Allergy Clin Immunol Pract},

volume = {1},

number = {6},

pages = {677-80},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN6033,

title = {[Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis]},

author = { S. Kleinert and K. Krueger and S. Stork},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23202996 

http://link.springer.com/article/10.1007%2Fs00393-011-0923-2},

doi = {10.1007/s00393-011-0923-2},

issn = {1435-1250 (Electronic) 

0340-1855 (Linking)},

year  = {2012},

date = {2012-01-01},

journal = {Z Rheumatol},

volume = {71},

number = {10},

pages = {850-8},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN6067,

title = {Renal perfusion in scleroderma patients assessed by microbubble-based contrast-enhanced ultrasound},

author = { S. Kleinert and P. Roll and C. Baumgaertner and A. Himsel and A. Mueller and M. Fleck and M. Feuchtenberger and M. Jenett and H. P. Tony},

url = {http://www.ncbi.nlm.nih.gov/pubmed/22670165 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367302/pdf/TORJ-6-50.pdf},

doi = {10.2174/1874312901206010050},

issn = {1874-3129 (Electronic)},

year  = {2012},

date = {2012-01-01},

journal = {Open Rheumatol J},

volume = {6},

pages = {50-3},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN6065,

title = {Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study},

author = { S. Kleinert and H. P. Tony and A. Krause and M. Feuchtenberger and S. Wassenberg and C. Richter and E. Rother and W. Spieler and H. Gnann and B. M. Wittig},

url = {http://www.ncbi.nlm.nih.gov/pubmed/21822659 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429775/pdf/296_2011_Article_2033.pdf},

doi = {10.1007/s00296-011-2033-5},

issn = {1437-160X (Electronic) 

0172-8172 (Linking)},

year  = {2012},

date = {2012-01-01},

journal = {Rheumatol Int},

volume = {32},

number = {9},

pages = {2759-67},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN6066,

title = {Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-gamma release assays under real-life conditions},

author = { S. Kleinert and H. P. Tony and K. Krueger and J. Detert and F. Mielke and K. Rockwitz and R. Schwenke and G. R. Burmester and R. Diel and M. Feuchtenberger and C. Kneitz},

url = {http://www.ncbi.nlm.nih.gov/pubmed/22586160 

http://ard.bmj.com/content/71/11/1791.full.pdf},

doi = {10.1136/annrheumdis-2011-200941},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2012},

date = {2012-01-01},

journal = {Ann Rheum Dis},

volume = {71},

number = {11},

pages = {1791-5},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8863,

title = {P67-phox (NCF2) lacking exons 11 and 12 is functionally active and leads to an extremely late diagnosis of chronic granulomatous disease (CGD)},

author = { J. Roesler and F. Segerer and H. Morbach and S. Kleinert and S. Thieme and A. Rosen-Wolff and J. G. Liese},

url = {https://www.ncbi.nlm.nih.gov/pubmed/22514628 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326000/pdf/pone.0034296.pdf},

doi = {10.1371/journal.pone.0034296},

issn = {1932-6203 (Electronic) 

1932-6203 (Linking)},

year  = {2012},

date = {2012-01-01},

journal = {PLoS One},

volume = {7},

number = {4},

pages = {e34296},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN5979,

title = {RF positivity has substantial influence on the peripheral memory B-cell compartment and its modulation by TNF inhibition},

author = { P. Roll and K. Muhammad and M. Schumann and S. Kleinert and H. P. Tony},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22400711 

http://informahealthcare.com/doi/abs/10.3109/03009742.2011.645056},

doi = {10.3109/03009742.2011.645056},

issn = {1502-7732 (Electronic) 

0300-9742 (Linking)},

year  = {2012},

date = {2012-01-01},

journal = {Scand J Rheumatol},

volume = {41},

number = {3},

pages = {180-5},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7618,

title = {Systemische Krankheitsmanifestationen und Komorbidität bei rheumatoider Arthritis},

author = { S Kleinert and U Müller-Ladner and M. Engelbrecht},

year  = {2012},

date = {2012-01-01},

journal = {Arthritis + rheuma},

volume = {4},

pages = {223-231},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN6034,

title = {Systemic manifestations of disease and comorbidities: cardiovascular risk and depression in patients with rheumatoid arthritis},

author = { S Kleinert and U Müller-Ladner and M. Englbrecht},

year  = {2012},

date = {2012-01-01},

journal = {arthritis + rheuma},

volume = {32},

pages = {223-231},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN5888,

title = {[Cardiovascular comorbidity and its risk factors in rheumatoid arthritis]},

author = { S. Kleinert and K. Krueger},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21863467},

doi = {10.1007/s00393-011-0755-0},

issn = {1435-1250 (Electronic) 

0340-1855 (Linking)},

year  = {2011},

date = {2011-01-01},

journal = {Z Rheumatol},

volume = {70},

number = {6},

pages = {464-72},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN5678,

title = {Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study},

author = { S. Kleinert and H. P. Tony and A. Krause and M. Feuchtenberger and S. Wassenberg and C. Richter and E. Rother and W. Spieler and H. Gnann and B. M. Wittig},

url = {http://www.ncbi.nlm.nih.gov/pubmed/21822659},

doi = {10.1007/s00296-011-2033-5},

issn = {1437-160X (Electronic) 

0172-8172 (Linking)},

year  = {2011},

date = {2011-01-01},

journal = {Rheumatol Int},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN5355,

title = {Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells},

author = { K. Muhammad and P. Roll and T. Seibold and S. Kleinert and H. Einsele and T. Dorner and H. P. Tony},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21551509 

http://ard.bmj.com/content/70/8/1507.full.pdf},

doi = {ard.2010.141325 [pii] 

10.1136/ard.2010.141325},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2011},

date = {2011-01-01},

journal = {Ann Rheum Dis},

volume = {70},

number = {8},

pages = {1507-10},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN5358,

title = {In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment},

author = { P. Roll and K. Muhammad and M. Schumann and S. Kleinert and H. Einsele and T. Dorner and H. P. Tony},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21305508 http://onlinelibrary.wiley.com/store/10.1002/art.30242/asset/30242_ftp.pdf?v=1&t=gq1xfjyd&s=8e8dcfd665fcfe97ab5497b4dc3297e1f3203654},

doi = {10.1002/art.30242},

issn = {1529-0131 (Electronic) 

0004-3591 (Linking)},

year  = {2011},

date = {2011-01-01},

journal = {Arthritis Rheum},

volume = {63},

number = {5},

pages = {1255-64},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN4596,

title = {[Systemic lupus erythematosus : A problem based approach.]},

author = { S. Kleinert and M. Feuchtenberger and H. P. Tony},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20628717 

http://www.springerlink.com/content/p7u21p561k27j100/fulltext.pdf},

doi = {10.1007/s00108-010-2682-6},

issn = {1432-1289 (Electronic) 

0020-9554 (Linking)},

year  = {2010},

date = {2010-01-01},

journal = {Internist (Berl)},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN4641,

title = {Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases},

author = { S. Kleinert and O. Kurzai and J. Elias and K. Marten and C. Engelke and M. Feuchtenberger and J. Sandstede and M. Frosch and H. P. Tony and C. Kneitz},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20185504 

http://ard.bmj.com/content/69/4/782.full.pdf},

doi = {ard.2009.113829 [pii] 

10.1136/ard.2009.113829},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2010},

date = {2010-01-01},

journal = {Ann Rheum Dis},

volume = {69},

number = {4},

pages = {782-4},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN94,

title = {Psoriatic arthritis: clinical spectrum and diagnostic procedures},

author = { S. Kleinert and M. Feuchtenberger and C. Kneitz and H. P. Tony},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18021887 http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T5G-4R4VVPN-6-7&_cdi=5002&_user=616166&_orig=search&_coverDate=12%2F31%2F2007&_sk=999749993&view=c&wchp=dGLbVtb-zSkWz&md5=6c5e6473a535b2a09d571ba91ddc2a7c&ie=/sdarticle.pdf},

doi = {S0738-081X(07)00148-4 [pii] 

10.1016/j.clindermatol.2007.08.004},

issn = {0738-081X (Print)},

year  = {2007},

date = {2007-01-01},

journal = {Clin Dermatol},

volume = {25},

number = {6},

pages = {519-23},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN5534,

title = {[Systemic sclerosis]},

author = { S. Kleinert and H. P. Tony and C. Kneitz},

url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16972070},

doi = {10.1007/s00108-006-1702-z},

issn = {0020-9554 (Print) 

0020-9554 (Linking)},

year  = {2006},

date = {2006-01-01},

journal = {Internist (Berl)},

volume = {47},

number = {10},

pages = {1051-61; quiz 1062},

keywords = {},

pubstate = {published},

tppubtype = {article}

}